Discontinued — last reported Q3 '25

Current Liabilities

Finance Lease Liability - Undiscounted Excess Amount

West Pharmaceutical Services Finance Lease Liability - Undiscounted Excess Amount decreased by 20.0% to $400.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 100.0%, from $200.00K to $400.00K. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLeverage
SignalLower is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ3 2025

How to read this metric

A higher amount indicates a larger interest component or longer lease terms, reflecting the total cash obligation beyond the current accounting valuation.

Detailed definition

This metric represents the difference between the total undiscounted future payments for finance leases and the present...

Peer comparison

Reported by companies with significant finance lease arrangements for capital equipment.

Metric ID: finance_lease_liability_undiscounted_excess

Historical Data

6 periods
 Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q1 '26
Value$300.00K$300.00K$200.00K$500.00K$500.00K$400.00K
QoQ Change+0.0%-33.3%+150.0%+0.0%-20.0%
YoY Change+66.7%+66.7%+100.0%
Range$200.00K$500.00K
CAGR+25.9%
Avg YoY Growth+77.8%
Median YoY Growth+66.7%

Frequently Asked Questions

What is West Pharmaceutical Services's finance lease liability - undiscounted excess amount?
West Pharmaceutical Services (WST) reported finance lease liability - undiscounted excess amount of $400.00K in Q1 2026.
How has West Pharmaceutical Services's finance lease liability - undiscounted excess amount changed year-over-year?
West Pharmaceutical Services's finance lease liability - undiscounted excess amount increased by 100.0% year-over-year, from $200.00K to $400.00K.
What does finance lease liability - undiscounted excess amount mean?
The total amount of future finance lease payments that exceeds the current liability recorded on the balance sheet.